

ORIGINAL ARTICLE

Species Identification of *Candida* Isolates from Critically Ill Patients by Rapid Commercial and Genotypic Methods

¹Rasha M. Elnagar*, ²Mohammad A. Ahmed, ¹Amira M. Sultan

¹Department of Medical Microbiology and Immunology, Faculty of Medicine, Mansoura University, Mansoura, Egypt

²Department of Anesthesia and Surgical Intensive Care, Faculty of Medicine, Mansoura University, Mansoura, Egypt

ABSTRACT

Key words:

Candida albicans,
CHROMagar™ *Candida*,
Vitek-2 system, ICU, non-
albicans Candida

*Corresponding Author:

Rasha Mokhtar Elnagar
Department of Medical
Microbiology & Immunology,
Faculty of Medicine, Mansoura
University, Mansoura, Egypt
Tel. +201095129425
E-mail address:
dr_rasha_m@mans.edu.eg

Background: Rapid, reliable *Candida* species (spp.) identification is crucial because it enables prompt and effective antifungal treatment. Unfortunately this is difficult due to a lack of knowledge, adequate reagents, and equipments, particularly in countries with limited resources. **Objectives:** The aim of this study was to assess the effectiveness of rapid commercial methods in identifying *Candida* spp. isolated from critically ill patients. **Methodology:** Various clinical specimens were collected from critically ill patients admitted to the Intensive Care Units of Mansoura University Hospitals, and processed by numerous mycological techniques. Gram stained, and lactophenol cotton blue stained films, as well, germ tube test, and corn meal agar with 1% Tween 80 were used to identify the isolated *Candida* spp. Three commercial methods were used for spp. identification; CHROMagar™ *Candida* medium, API 20 C AUX and Vitek-2 Compact automated system. In addition, all *Candida* isolates were subjected to species-specific multiplex PCR as the reference method. **Results:** A total of 52 *Candida* strains were identified where *C. albicans* was the predominant spp. (53.8%) followed by *C. parapsilosis* (17.3%), *C. glabrata* (13.5%), *C. dubliniensis* (5.8%), *C. tropicalis* (5.8%), *C. auris* (1.9%) and *C. krusei* (1.9%). Both CHROMagar™ *Candida* medium and Vitek-2 Compact automated system exhibited high sensitivity and specificity rates in identification of various *Candida* spp. as compared to multiplex PCR. **Conclusion:** This study demonstrated a good performance of both CHROMagar™ *Candida* medium and Vitek-2 Compact automated system; however, CHROMagar™ *Candida* medium may be an easier and more cost-effective choice to identify *Candida* spp., mainly in areas with restricted resources.

INTRODUCTION

Candida species (spp.) are part of the commensal microbiota of skin, gastrointestinal tract, and respiratory mucosa; however, they can cause opportunistic infections with impaired immune system¹. *Candida* has become a major nosocomial pathogen among critically ill immunocompetent and immunocompromised patients for a variety of reasons, such as increased numbers of bone marrow and solid organ recipients, neutropenia, malignancy, overuse of broad spectrum antibiotics and prior surgery. Other risk factors for nosocomial candidiasis include; prolonged stay in the intensive care units (ICUs), total parenteral nutrition and the use of central lines and other invasive devices².

The most prevalent *Candida* infections among ICUs patients are bloodstream infections, surgical site infections, respiratory and urinary tract infections. Candidemia is potentially fatal, and is linked to high morbidity and fatality rates³. Various studies stated that *Candida albicans* (*C. albicans*) is still the commonest *Candida* spp. recovered from invasive candidiasis (IC), despite the fact that isolation rates of non-albicans

Candida (NAC) spp. displayed resistance to typical antifungal medications have dramatically increased recently⁴. Among NAC strains associated with IC are *C. parapsilosis*, *C. glabrata*, *C. tropicalis*, *C. kefyr*, *C. guilliermondii*, and *C. Krusei*⁵. The development of more advanced diagnostic techniques has aided in the discovery of novel NAC species, such as *C. auris*, which was isolated from numerous nosocomial *Candida* infections worldwide⁶.

Because of the heterogeneity in the epidemiology of *Candida* infections and the use of novel antifungal agents with diverse spectrums, therapeutic decisions made by physicians may no longer be based solely on the classification of *Candida* as either *C. albicans* or NAC⁷. Therefore, prompt and accurate identification of *Candida* spp. is essential for the efficient treatment of *Candida* infections. Clinical microbiology and research laboratories use a variety of techniques to detect *Candida* spp⁸.

Standard conventional methods, based on morphological characters, have been used to identify various *Candida* spp. such as the germ tube test which can differentiate between germ tube-positive spp.

including *C. albicans*, *C. stellatoidea*, and *C. dubliniensis* from the other germ tube-negative spp., and chlamydo-spore production on cornmeal agar which takes 24–72 h⁹. Besides, biochemical reactions as sugar assimilation and fermentation have been used to differentiate between *Candida* spp. These detection methods are tiresome and time-consuming¹⁰. Several commercial diagnostic techniques are now available as chromogenic media, API 20 C and automated Vitek-2 Compact system which can help in precise identification of *Candida* spp¹¹.

CHROMagarTM *Candida* medium is a selective differential chromogenic medium used to isolate and ostensibly identify distinct *Candida* spp. based on their color¹². Another commercial approach for differentiating between *Candida* spp. is the API 20 C system. It is composed of 20 cupules that allow for the execution of 19 assimilation tests. In this method, yeast cells will only proliferate if they can use the dehydrated substrate as their sole supply of carbon¹³.

Various infections, including *Candida*, can be identified and tested for antimicrobial sensitivity using the fully automated Vitek-2 Compact system. It is a quick method that can in 18 h identify microbes down to the species level, compared to 48–72 h in other approaches, by using Vitek-2 cards that allow species identification by comparing the resulting biochemical profile to a large database¹⁴. In addition to these techniques, DNA-based approaches also aid in the differentiation of distinct *Candida* spp. with high sensitivity and specificity¹⁵.

This study intended to (i) investigate the distribution of various *Candida* spp. among clinical samples collected from critically ill patients (ii) compare the effectiveness of three commercial methods for identifying *Candida* spp., including CHROMagarTM *Candida* medium, API 20 C AUX system, and Vitek-2 Compact automated system with species-specific PCR.

METHODOLOGY

Ethical approval statement

The institutional research board at Mansoura Faculty of Medicine, Egypt gave the study its approval and assigned it the protocol number R.22.09.1814.

Study design and samples collection:

This prospective study was carried out during the period extended from July 2021 to June 2022. Various clinical specimens were collected from severely ill patients, with suspected candidiasis, who were admitted to the ICUs at Mansoura University Hospitals, Egypt. Samples were transferred to the Mycology Lab, Medical Microbiology and Immunology Department, Faculty of Medicine, Mansoura University, Egypt within 2 h after collection.

Samples processing and mycological examination:

All clinical samples were prepared for the isolation of *Candida* strains following established mycological protocols. First, *Candida* growth was obtained by streaking of samples on Sabouraud's dextrose agar (SDA) plates supplemented with chloramphenicol (50 µg/ml) (Oxoid, UK), then were incubated aerobically at 37°C for 24 h. Gram stained, and lactophenol cotton blue stained films, in addition to, germ tube tests, and subculture on corn meal agar (Oxoid, UK) with 1% Tween 80 (Sigma, Aldrich) were used to identify the isolated *Candida*¹⁶.

Identification of *Candida* species by rapid commercial methods:

CHROMagarTM *Candida* medium

The isolated *Candida* colonies were sub-cultured on CHROMagarTM *Candida* medium (CHROMagar, France). Following incubation of the plates for 48 h at 37°C, the growth was interpreted per manufacturer's instructions¹⁷.

API 20 C AUX system

The API 20 C AUX system (Bio-Merieux, France) was also used for differentiation of *Candida* spp. The cupules turbidity was identified after incubation at 37°C for 24–72 h by using the analytical profile index and reading them as compared to the growth control (0 cupule)¹⁸.

Vitek-2 Compact automated system

Moreover, the Vitek-2 Compact automated system (Bio-Mérieux, France) was used to identify *Candida* spp. *Candida* suspensions of 1.8–2.2 McFarland standard were loaded onto the identification cards and incubated for 18 h. Following incubation, the results shown on the cards were compared with an identification database¹⁴.

Reference strains *C. albicans* (ATCC 24433), *C. krusei* (ATCC 6258), *C. tropicalis* (0750), *C. glabrata* (ATCC 90030) and *C. parapsilosis* (ATCC 22019) were used as quality control. *Candida* isolates were stored in medium containing 20% glycerol at –80°C for further molecular identification.

Genotypic detection of *Candida* spp. by species-specific multiplex PCR:

The multiplex PCR technique was used to identify the study isolates using universal primers that target the internal transcribed spacer region (ITS) and *Candida* species-specific primers (Sigma, Aldrich) as shown in table 1^{19,23}.

Candida DNA was extracted from fresh *Candida* subculture on SDA using Zymo DNA mini kit (Zymo, USA) according to the manufacturers' instructions. The PCR reaction was conducted in 50 µl reaction mix containing 25 µl of 2X GoTaq Green Master Mix (Willowfort, UK), 5 µl of genomic DNA, 1 µl from each universal and species-specific forward and reverse primers and 2 µl DNase free water. The PCR conditions were as follows: initial denaturation step for 5 min at

96°C, forty cycles of: denaturation at 94°C for 30 sec, annealing at 58°C for 30 sec, extension at 72°C for 30 sec, followed by a final extension step for 15 min at 72°C²⁴.

Utilizing the UV transilluminator (FBTIV-88, Fisher, USA), the amplified PCR products were

detected by using 2% agarose gel electrophoresis. Based on the size of the fragments in contrast to a 100 bp DNA marker (Lonza Rockland Inc., USA), *Candida* spp. identification was made²⁵.

Table 1. Primers used for identification of *Candida* species

<i>Candida</i> species	Targeted gene	Primer sequences (5' to 3')	Amplicon size (bp)	Reference
Universal primers	<i>ITS1</i> <i>ITS2</i>	TCC GTA GGT GAA CCT GCG G GCT GCG TTC TTC ATC GAT GC	–	19
<i>C. albicans</i>	<i>CalbF</i> <i>CalbR</i>	TGGTAAGGCGGGATCGCTT GGTCAAAGTTTGAAGATATAC	446	20
<i>C. dubliniensis</i>	<i>CdubF</i> <i>CdubR</i>	AACTTGTACGAGATTATTTTT AAAGTTTGAAGAATAAAATGGC	217	20
<i>C. glabrata</i>	<i>CglaF</i> <i>CglaR</i>	TCACTTTCAACTGCTTTTCGC TGCGAGTCATGGGCGGAA	482	21
<i>C. parapsilosis</i>	<i>PparF</i> <i>CparR</i>	GCGGAAGGATCATTACAGAATG CTGGCAGGCCCATATAG	229	21
<i>C. tropicalis</i>	<i>CtroF</i> <i>CtroR</i>	AGACACGACTTTTTTCGCATTTTTTC TTCCACAGCTTCAACCAATGCAA	218	22
<i>C. krusei</i>	<i>CkF</i> <i>CkR</i>	TGTGGAATATAGCATATAGTCGACA CAACTCTGCGCACGCGCAAGAT	182	22
<i>C. auris</i>	<i>CauF</i> <i>CauR</i>	CGCACATTGCGCCTTGGGGTA GTAGTCCTACCTGATTTGAGGCGAC	215	23
<i>C. lusitaniae</i>	<i>ClusF</i> <i>ClusR</i>	GCGATACGTAGTATGACTTGCAGACG CAGCGGGTAGTCCTACCTGA	203	23

Note: bp, base pair.

Statistical Analysis

The statistical package of SPSS version 23 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Values were expressed as numbers and percentages. Mean \pm standard deviation (SD) were used to express parametric data. Sensitivity and specificity of the various testing procedures were assessed by using species-specific multiplex PCR as the gold standard method.

RESULTS

During our study, 52 non-repetitive *Candida* strains were recovered, by both phenotypic and genotypic techniques, from different clinical samples. Out of these 52 isolates, 28 (53.8%) were *C. albicans* and 24 (46.2%) were NAC. Various *Candida* spp. were illustrated in table 2. Among the study participants, 19 (36.5%) were females while 33 (63.5%) were males with an age range from 26–70 years (Mean: 46.7, SD: 10.0).

Table 2: Distribution of *Candida albicans* and non-*albicans Candida* isolates among the study participants

<i>Candida</i> species (n=52)	No.	%
<i>C. albicans</i>	28	53.8
Non- <i>albicans Candida</i>	24	46.2
<i>C. parapsilosis</i>	9	17.3
<i>C. glabrata</i>	7	13.5
<i>C. dubliniensis</i>	3	5.8
<i>C. tropicalis</i>	3	5.8
<i>C. krusei</i>	1	1.9
<i>C. auris</i>	1	1.9

Among the isolated *Candida*, 19 (36.5%) showed evidence of germ tube production, while 33 (63.5%) were negative (figure 1). The 19 positive strains were further confirmed as *C. albicans* by multiplex PCR. On corn meal agar with 1% Tween 80, 22 strains (42.3%), and 3 strains (5.8%) were identified as *C. albicans* and *C. dubliniensis*, respectively with typical chlamydospores formation (figure 2). As opposed to that, 27 (51.9%) *Candida* strains couldn't be speciated by the corn meal agar.




Fig. 1: Positive germ tube formation of *Candida* isolates in fresh human serum at 37°C for 4 h (40x).



Fig. 2: Subculture of *Candida* species on corn meal agar with 1% Tween 80 showing yeast cells, pseudohyphae and chlamydo spores (40x).

Additionally to these conventional methods, we used three commercial procedures for the species detection of *Candida* isolates: CHROMagar™ *Candida* medium, API 20 C AUX and Vitek-2 Compact automated system. By subculture of *Candida* growth on CHROMagar™ *Candida* medium, different color degrees of *Candida* colonies were observed as shown in (figure 3). This chromogenic media identified 28 (53.8%) strains as *C. albicans*, 4 (7.7%) as *C. glabrata*, 3 (5.8%) as *C. dubliniensis*, 3 (5.8%) as *C. tropicalis* and 1 (1.9%) as *C. krusei*. By this diagnostic test, 13 (25.0%) strains couldn't be differentiated as their colors were doubtful. These 13 isolates were further identified as *C. parapsilosis*, *C. glabrata* and *C. auris* by multiplex PCR.




Fig. 3: Different *Candida* species on CHROMagar™ *Candida* medium at 37 °C for 48 hours (a): *C. albicans*; (b) and (d): *C. dubliniensis*; (c): *C. Krusei*; (e) and (f): *C. tropicalis*; (g) and (h): *C. glabrata*.

In our study, the API 20 C AUX system classified the *Candida* strains into 25 (48.1%) *C. albicans*, 5 (9.6%) *C. parapsilosis*, 3 (5.8%) *C. dubliniensis*, 3 (5.8%) *C. glabrata*, 2 (3.8%) *C. tropicalis* and 1 (1.9%) *C. krusei*. On the other hand, this diagnostic technique was unable to differentiate between a total of 13 (25.0%) strains. Notably, the Vitek 2 automated system was able to identify all the isolated 52 *Candida* strains, and among them, 28 (53.8%) were *C. albicans*, 9 (17.3%) were *C. parapsilosis*, 7 (13.5%) were *C. glabrata*, 3 (5.8%) were *C. dubliniensis*, 3 (5.8%) were *C. tropicalis*, 1 (1.9%) was *C. auris* and 1 (1.9%) was *C. krusei*. These results were confirmed by multiplex PCR.

Molecular examination of the 52 *Candida* strains by multiplex PCR revealed the following spp.; *C. albicans* (28, 53.8%), *C. parapsilosis* (9, 17.3%), *C. glabrata* (7, 13.5%), *C. dubliniensis* (3, 5.8%), *C. tropicalis* (3, 5.8%), and each of *C. auris* and *C. krusei* was (1, 1.9%).

The results of conventional and rapid commercial methods were compared with multiplex PCR which is the reference standard (figure 4). The CHROMagar™ *Candida* medium and Vitek-2 Compact automated system exhibited high specificity and sensitivity rates in identification of *Candida* spp. The performances of various diagnostic methods were illustrated in table 3.




Fig. 4: Identification of *Candida* isolates by different diagnostic methods.

Table 3. Sensitivity and specificity of different methods used for *Candida* species identification in relation to multiplex PCR as the gold standard

Performance	Diagnostic test	<i>Candida</i> species (n=52)						
		<i>C. albicans</i>	<i>C. parapsilosis</i>	<i>C. glabrata</i>	<i>C. dubliniensis</i>	<i>C. tropicalis</i>	<i>C. krusei</i>	<i>C. auris</i>
Sensitivity	Germ tube test	67.9%	-	-	-	-	-	-
	Corn meal agar with Tween 80	78.6%	-	-	100%	-	-	-
	CHROMagar™ <i>Candida</i> medium	100%	-	57.1%	100%	100%	100%	-
	API 20 C AUX	89.3%	55.6%	42.9%	100%	66.7%	100%	-
	Vitek-2 Compact automated system	100%	100%	100%	100%	100%	100%	100%
Specificity	Germ tube test	100%	-	-	-	-	-	-
	Corn meal agar with Tween 80	100%	-	-	100%	-	-	-
	CHROMagar™ <i>Candida</i> medium	100%	-	100%	100%	100%	100%	-
	API 20 C AUX	100%	100%	100%	100%	100%	100%	-
	Vitek-2 Compact automated system	100%	100%	100%	100%	100%	100%	100%

Regarding the *Candida* spp. distribution among various samples, 26 strains were recovered from blood (15, 57.7% *C. albicans*; 8, 30.8% *C. parapsilosis*; and 3, 11.5% *C. glabrata*), and 12 from endotracheal aspirates (8, 66.7% *C. albicans*; 2, 16.7% *C. glabrata*; 1, 8.3% for each *C. dubliniensis*, and *C. tropicalis*),

followed by 4 from sputum (2, 50.0% *C. albicans*, 1, 25.0% *C. krusei*, and 1, 25.0% *C. dubliniensis*). Overall, 10 strains were isolated from urine specimens (3, 30.0% *C. albicans*; 2, 20.0% for each *C. glabrata*, and *C. tropicalis*; followed by 1, 10.0% for each *C. parapsilosis*, *C. auris*, and *C. dubliniensis*) (figure 5).




Fig. 5: Distribution of *Candida* species among various clinical specimens

DISCUSSION

Invasive candidiasis is a dangerous and potentially fatal condition with exceedingly high morbidity and fatality rates among individuals with critical illnesses²⁶. Non-albicans *Candida* has gained a grave concern worldwide owing to the high proportions of *Candida* infections among severely ill patients caused by NAC. Furthermore, several NAC spp. are linked to increased incidence of inherent resistance to various antifungal medications that are frequently used to treat fungal infections. Therefore, treating infections caused by NAC spp. can be challenging to physicians which could increase mortality rates especially among ICU patients²⁷.

Nowadays, a variety of kit-based commercial and molecular approaches for *Candida* spp. identification are available²⁸. While some of these methods can detect *Candida* isolates directly from clinical specimens, others necessitate the isolation of *Candida* beforehand. These approaches vary in principle, cost, specificity and sensitivity rates and each has benefits and drawbacks of its own²⁹. It is crucial that clinical laboratories implement a method that is accurate and practical for identifying *Candida* spp. so that timely and suitable antifungal therapy can be initiated in order to save lives³⁰. However, in low income countries with limited resources, laboratories restrict the diagnosis to *C.*

albicans or NAC to reduce the financial burden and most of them usually do not proceed further than the germ tube test⁹.

In the current work, 52 *Candida* strains were recovered from samples collected from critically ill patients. Half of these strains were recovered from blood stream infections and 30.8% were recovered from respiratory tract infections. Our results were in line with a previous study which reported that 45.2% of their subjects had candidemia and 25.8% had respiratory infections³¹. Although high prevalence of NAC strains (46.2%) was identified in the present work, *C. albicans* (53.8%) still represented the majority of strains isolated from critically ill patients in our locality. Among the isolated NAC, *C. parapsilosis* (17.3%) and *C. glabrata* (13.5%) represented the majority of spp. Our results were consistent with a previous study from Egypt that reported high prevalence rates of *C. albicans* among ICU patients followed by NAC³². In addition, a former study conducted in Iran has reported that *C. albicans* was the commonest cause of *Candida* infection (62.4%), followed by *C. parapsilosis* (17.5%) and *C. glabrata* (8.8%)²⁵. Besides, another study from Germany declared that 60.9% of their isolates were *C. albicans* followed by *C. glabrata* (19.4%), and *C. parapsilosis* (6.6%)³. In contrast to our results, a former study from India reported *C. tropicalis* as the commonest *Candida* spp. followed by *C. albicans*³³. Such discrepancy may be attributed to geographical

variations and differences in antifungals regimen between countries.

Numerous conventional methods, including the germ tube test and cornmeal agar with 1% tween 80, have been established for the speciation of *Candida*³⁴. However, in the present study, most of the *Candida* strains couldn't be differentiated by these methods. Numerous researches have assessed how far the alternative commercially available techniques for identification of *Candida* isolates function³⁵. In the present study, three commercial methods (API 20 C AUX, CHROMagar™ *Candida* medium and Vitek-2 Compact automated system) were evaluated for their accuracy in discrimination of *Candida* isolates in respect with multiplex PCR as the reference method.

In the present study, 25.0% of *Candida* isolates couldn't be identified up to species level with API 20 C AUX system. The sensitivity of this test in identifying *C. albicans* was 89.3%, compared to 100% sensitivity and specificity of both CHROMagar™ *Candida* medium and Vitek-2 Compact automated system. This was in line with the findings of another study³⁶. Sariguzel *et al.*¹⁴ agreed with our results regarding the CHROMagar™ *Candida* medium and Vitek-2 Compact automated system. In contrast to our results, Malik and his colleagues proved the superiority of API 20 C AUX to CHROMagar™ *Candida* medium in identifying *Candida* spp.³⁷

Notably, Vitek-2 Compact automated system and multiplex PCR results were quite consistent in identification of both *C. albicans* and NAC spp. with high sensitivity and specificity rates (100%). However, PCR requires more tools and reagents, so Vitek-2 system may be preferred in localities where resources are available. A preceding study from Turkey agreed with our findings¹⁴.

CHROMagar™ *Candida* medium is a readily accessible chromogen-based culture medium that has been evaluated in the current work. Although, colors of some *Candida* strains were doubtful and some spp. couldn't be identified by CHROMagar™ *Candida* medium, this did not detract from its efficiency in differentiation of various *Candida* spp. This was in line with a foregoing Indian study that conveyed respectable performance of CHROMagar™ *Candida* medium and Vitek-2 Compact automated system as diagnostic techniques³⁸. A study performed by Mathavi and his colleagues has demonstrated a high degree of precision of CHROMagar™ *Candida* medium in the discrimination of diverse *Candida* spp.¹⁷ Furthermore, another study documented accurate species identification of *Candida* isolates using CHROMagar™ *Candida* medium³⁹. Besides, a prior work by Scharmann *et al.*¹² confirmed the efficacy of this medium in differentiation of *Candida* spp. Moreover, a prior study from Egypt agreed with our results⁴⁰.

CONCLUSION

Despite the Vitek-2 Compact automated system's accuracy and benefits in both speciation of *Candida* spp., and determination of antifungal susceptibility, its high cost makes it unsuitable for low-income countries. Similarly, the API 20 C AUX is laborious, time-consuming, and subject to individual errors as it depends on turbidity measurement. On the other side, CHROMagar™ *Candida* medium has the benefits of rapid detection of *Candida* spp., technically straightforward preparation, and cost effectiveness. Therefore, it may be considered a cheaper and accurate alternative for Vitek-2 Compact automated system and molecular techniques in developing countries with low resources.

This manuscript has not been previously published and is not under consideration in the same or substantially similar form in any other reviewed media. I have contributed sufficiently to the project to be included as author. To the best of my knowledge, no conflict of interest, financial or others exist. All authors have participated in the concept and design, analysis, and interpretation of data, drafting and revising of the manuscript, and that they have approved the manuscript as submitted.

REFERENCES

1. Alenazy H, Alghamdi A, Pinto R, Daneman N. *Candida* colonization as a predictor of invasive candidiasis in non-neutropenic ICU patients with sepsis: A systematic review and meta-analysis. *Int J Infect Dis.* 2021;102:357-362. doi:10.1016/j.ijid.2020.10.092
2. Ahmad S, Kumar S, Rajpal K, et al. Candidemia Among ICU Patients: Species Characterisation, Resistance Pattern and Association with Candida Score: A Prospective Study. *Cureus.* 2022;14(4):e24612. doi:10.7759/cureus.24612
3. Schroeder M, Weber T, Denker T, et al. Epidemiology, clinical characteristics, and outcome of candidemia in critically ill patients in Germany: a single-center retrospective 10-year analysis. *Ann Intensive Care.* 2020;10(1):142. doi:10.1186/s13613-020-00755-8
4. Soulountsi V, Schizodimos T, Kotoulas SC. Deciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible? *Infection.* 2021;49(6):1107-1131. doi:10.1007/s15010-021-01640-7

5. Pfaller MA, Andes DR, Diekema DJ, et al. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of *Candida* in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. *PLoS One*. 2014;9(7):e101510. doi:10.1371/journal.pone.0101510
6. Piatti G, Sartini M, Cusato C, Schito AM. Colonization by *Candida auris* in critically ill patients: role of cutaneous and rectal localization during an outbreak. *J Hosp Infect*. 2022;120:85-89. doi:10.1016/j.jhin.2021.11.004
7. Giacobbe DR, Maraolo AE, Simeon V, et al. Changes in the relative prevalence of candidaemia due to non-albicans *Candida* species in adult in-patients: A systematic review, meta-analysis and meta-regression. *Mycoses*. 2020;63(4):334-342. doi:10.1111/myc.13054
8. Sankari SL, Mahalakshmi K, Kumar VN. A comparative study of *Candida* species diversity among patients with oral squamous cell carcinoma and oral potentially malignant disorders. *BMC Res Notes*. 2020;13(1):488. doi:10.1186/s13104-020-05336-3
9. Marinho SA, Teixeira AB, Santos OS, et al. Identification of *Candida* spp. by phenotypic tests and PCR. *Braz J Microbiol*. 2010;41(2):286-294. doi:10.1590/S1517-83822010000200004
10. Jafarian H, Gharaghani M, Asnafi AA, et al. Phenotype, genotype, and mating type determination in oral *Candida albicans* isolates from pediatric patients with neutropenia. *J Clin Lab Anal*. 2022; e24664. doi:10.1002/jcla.24664
11. Mulet Bayona JV, Salvador García C, Tormo Palop N, et al. Novel Chromogenic Medium CHROMagar™ *Candida* Plus for Detection of *Candida auris* and Other *Candida* Species from Surveillance and Environmental Samples: A Multicenter Study. *J Fungi (Basel)*. 2022;8(3):281. doi:10.3390/jof8030281
12. Scharmann U, Kirchhoff L, Chapot VLS, et al. Comparison of four commercially available chromogenic media to identify *Candida albicans* and other medically relevant *Candida* species. *Mycoses*. 2020;63(8):823-831. doi:10.1111/myc.13119
13. Arastehfar A, Daneshnia F, Kord M, et al. Comparison of 21-Plex PCR and API 20C AUX, MALDI-TOF MS, and rDNA Sequencing for a Wide Range of Clinically Isolated Yeast Species: Improved Identification by Combining 21-Plex PCR and API 20C AUX as an Alternative Strategy for Developing Countries. *Front Cell Infect Microbiol*. 2019;9:21. doi:10.3389/fcimb.2019.00021
14. Sariguzel FM, Berk E, Koc AN, Sav H, Aydemir G. Evaluation of chromogenic agar, VITEK2 YST and VITEK® MS for identification of *Candida* strains isolated from blood cultures. *Infez Med*. 2015;23(4):318-322.
15. Hassan Y, Aminu I, Abdullahi SA. *Candida* Diagnostic Platforms: Essential in Early Management of *Candida* Infections. *Fudma J Sci*. 2021;5(2), 59-71. doi:10.33003/fjs-2021-0502-522
16. Neppelenbroek KH, Seó RS, Urban VM, et al. Identification of *Candida* species in the clinical laboratory: a review of conventional, commercial, and molecular techniques. *Oral Dis*. 2014; 20(4): 329-344. doi:10.1111/odi.12123
17. Mathavi S, Sasikala G, Kavitha A, et al. CHROMagar as a primary isolation medium for rapid identification of *Candida* and its role in mixed *Candida* infection in sputum samples. *Indian J Microbiol Res*. 2016;3(2):141-144. doi:10.5958/2394-5478.2016.00033.9
18. Sudhan SS, Sharma P, Sharma M, et al. Identification of *Candida* Species in the Clinical Laboratory: A review of conventional, commercial and molecular techniques. *Int J Med Res Prof*. 2016;2(6):1-8. doi: 10.21276/ijmrp.2016.2.6.001
19. Liguori G, Gallé F, Lucariello A, et al. Comparison between multiplex PCR and phenotypic systems for *Candida* spp. identification. *New Microbiol*. 2010;33(1):63-67.
20. Ahmad S, Khan Z, Asadzadeh M, Theyyathel A, Chandy R. Performance comparison of phenotypic and molecular methods for detection and differentiation of *Candida albicans* and *Candida dubliniensis*. *BMC Infect Dis*. 2012;12:230. doi:10.1186/1471-2334-12-230
21. Arastehfar A, Fang W, Pan W, Liao W, Yan L, Boekhout T. Identification of nine cryptic species of *Candida albicans*, *C. glabrata*, and *C. parapsilosis* complexes using one-step multiplex PCR. *BMC Infect Dis*. 2018;18(1):480. doi:10.1186/s12879-018-3381-5
22. Carvalho A, Costa-De-Oliveira S, Martins ML, et al. Multiplex PCR identification of eight clinically relevant *Candida* species. *Med Mycol*. 2007;45(7):619-627. doi:10.1080/13693780701501787
23. Kordalewska M, Zhao Y, Lockhart SR, Chowdhary A, Berrio I, Perlin DS. Rapid and Accurate Molecular Identification of the Emerging Multidrug-Resistant Pathogen *Candida auris*. *J Clin*

- Microbiol. 2017;55(8):2445-2452. doi:10.1128/JCM.00630-17
24. Tellapragada C, Eshwara VK, Johar R, et al. Antifungal susceptibility patterns, in vitro production of virulence factors, and evaluation of diagnostic modalities for the speciation of pathogenic *Candida* from blood stream infections and vulvovaginal candidiasis. *J Pathog.* 2014;2014:142864. doi:10.1155/2014/142864
 25. Sadrossadati SZ, Ghahri M, Imani Fooladi AA, Sayyahfar S, Beyraghi S, Baseri Z. Phenotypic and genotypic characterization of *Candida* species isolated from candidemia in Iran. *Curr Med Mycol.* 2018;4(2):14-20. doi:10.18502/cmm.4.2.64
 26. Bassetti M, Giacobbe DR, Vena A, et al. Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. *Crit Care.* 2019;23(1):219. doi:10.1186/s13054-019-2497-3
 27. Xia J, Huang W, Lu F, Li M, Wang B. Comparative Analysis of Epidemiological and Clinical Characteristics Between Invasive *Candida* Infection versus Colonization in Critically Ill Patients in a Tertiary Hospital in Anhui, China. *Infect Drug Resist.* 2022;15:3905-3918. doi:10.2147/IDR.S368792
 28. Camp I, Spettel K, Willinger B. Molecular Methods for the Diagnosis of Invasive Candidiasis. *J Fungi (Basel).* 2020;6(3):101. doi:10.3390/jof6030101
 29. Sattler J, Noster J, Brunke A, et al. Comparison of Two Commercially Available qPCR Kits for the Detection of *Candida auris*. *J Fungi (Basel).* 2021;7(2):154. doi:10.3390/jof7020154
 30. Man A, Ciurea CN. *Candida* Identification and Genotyping-A Challenge for the Medical Laboratory. *Roum Arch Microbiol Immunol.* 2021;80(2):189-191.
 31. Peres-Bota D, Rodriguez-Villalobos H, Dimopoulos G, Melot C, Vincent JL. Potential risk factors for infection with *Candida* spp. in critically ill patients. *Clin Microbiol Infect.* 2004;10(6):550-555. doi:10.1111/j.1469-0691.2004.00873.x
 32. M El-Ganiny A, E Yossef N, A Kamel H. Prevalence and antifungal drug resistance of nosocomial *Candida* species isolated from two university hospitals in Egypt. *Curr Med Mycol.* 2021;7(1):31-37. doi:10.18502/cmm.7.1.6181
 33. Giri S, Kindo AJ. Evaluation of five phenotypic tests in the identification of *Candida* species. *Natl J lab med.* 2015;4(4):13-18. doi: 0.7860/NJLM/2015/13492:2057
 34. Martínez-Lamas L, Pérez del Molino ML, Pardo F, Varela E, Regueiro BJ. Espectrometría de masas matrix-assisted laser desorption ionization time-of-flight vs. metodología convencional en la identificación de *Candida* no-albicans [Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry vs conventional methods in the identification of *Candida* non-albicans]. *Enferm Infecc Microbiol Clin.* 2011;29(8):568-572. doi:10.1016/j.eimc.2011.03.014
 35. Bustamante B, Martins MA, Bonfietti LX, et al. Species distribution and antifungal susceptibility profile of *Candida* isolates from bloodstream infections in Lima, Peru. *J Med Microbiol.* 2014;63(Pt 6):855-860. doi:10.1099/jmm.0.071167-0
 36. Gündeş SG, Gulenc S, Bingol R. Comparative performance of Fungichrom I, Candifast and API 20C Aux systems in the identification of clinically significant yeasts. *J Med Microbiol.* 2001;50(12):1105-1110. doi:10.1099/0022-1317-50-12-1105
 37. Malik UM, Khan AB, Satti ML. Comparative evaluation of CHROMagar and API 20C AUX in isolation and identification of *Candida* species. *J Islam Int Med Coll.* 2018;13(2):85-90.
 38. Bhaskaran R, Valsan C, Sathiyavathy KA. Evaluation of the four phenotypic methods for the speciation of *Candida* isolates in comparison with molecular method. *Indian J Microbiol Res.* 2020;7(2):168-174. doi:10.18231/j.ijmr.2020.030
 39. Rajkumari S, Adhikaree N. Speciation of *Candida* using CHROMagar from Various clinical Specimens and their Antifungal Susceptibility Pattern at a Tertiary Care Hospital. *JCMS-Nepal.* 2020;16(2):107-111. doi:10.3126/jcmsn.v16i2.29896
 40. Daef E, Moharram A, Eldin SS, Elsherbiny N, Mohammed M. Evaluation of chromogenic media and seminested PCR in the identification of *Candida* species. *Braz J Microbiol.* 2014;45(1):255-262. doi:10.1590/S1517-83822014005000040